Bayer's China Approval Adds a Second Front to a Pharma-Led Turnaround
Published on 11/04/2026 at 13:31 | Editorial boerse-global.de
Bayer picked up Chinese regulatory clearance for Sevabertinib on Tuesday, giving the group a fresh first-line treatment option in a tightly defined patient group. The approval covers adults with unresectable, locally advanced or metastatic HER2-mutated non-small cell lung cancer. It lands barely a day after the company raised its full-year outlook on the back of a stronger-than-expected pharmaceuticals division — two developments that investors will need to weigh on separate scales.
The shares added 2.9% on the day, though no clear link between the move and the approval can be drawn. The prior session's advance of 3.7% was attributed by Reuters to the better-than-expected pharma performance and the upgraded guidance.
What the upgrade actually contains
Bayer now expects currency-adjusted EBITDA before special items of EUR 9.8bn to 10.3bn for 2026, lifted from a previous range of EUR 9.6bn to 10.1bn. Free cash flow guidance was also improved, to between minus EUR 1.5bn and minus EUR 0.5bn from minus EUR 2.5bn to minus EUR 1.5bn — an upgrade that still leaves the cash register running in reverse.
The third quarter delivered group revenue of EUR 10.053bn and EBITDA before special items of EUR 1.615bn, up 6.9%. Pharma was the engine: the division's EBITDA before special items climbed 23.6% to EUR 1.292bn. Adjusted earnings per share came in at EUR 0.31, while the group posted a net loss of EUR 0.7bn and negative free cash flow of EUR 0.3bn. Net financial debt stood at EUR 31.1bn.
Should investors sell immediately? Or is it worth buying Bayer?
The sell side is split down the middle
Deutsche Bank Research kept its "Buy" rating and EUR 60 price target after the quarterly figures, backing a constructive reading of the stock. JPMorgan was more emphatic still, reaffirming "Overweight" with a EUR 61 target; analyst Richard Vosser pointed to the strength of the pharma business, the positive EBITDA surprise and the more optimistic outlook.
Jefferies, by contrast, stayed at "Hold" with a EUR 46 target. Analyst Michael Leuchten acknowledged the positive surprises on revenue and adjusted EBITDA but flagged core earnings per share below consensus — a reminder that headline beats and per-share reality do not always move in step.
A courtroom calendar that will not wait
None of this makes the legal overhang disappear. Chief executive Bill Anderson expects a court ruling on the proposed Roundup settlement before Christmas, according to Reuters. The proposal carries a volume of USD 7.25bn and has yet to receive judicial approval.
There was a courtroom win on Friday, when Bayer subsidiary Monsanto prevailed in Missouri against three plaintiffs. The jury ruled unanimously in Monsanto's favour on the claims of product defect, fraud and negligence, per company statements. That verdict is a separate matter from the pending settlement decision and should not be read as a signal on it.
How the two scenarios stack up
The bull case pairs the already-reported earnings improvement with further commercial upside from the pharma pipeline. Should Sevabertinib eventually make a meaningful contribution, it would reinforce confidence in the earnings trajectory — but the Chinese approval is a starting point, not a booked revenue or profit effect. An approval is not proof of a given economic contribution.
Bayer at a turning point? This analysis reveals what investors need to know now.
The bear case has two entry points: expectations for the pharma business could prove too rich, and the settlement ruling could land differently than investors hope. A positive regulatory headline would not, on its own, offset both.
What matters for the valuation is whether Bayer can convert pharma strength into a durable earnings record. The approval should be read alongside group earning power, not in isolation — a broadly evidenced earnings trend would carry more weight than hopes pinned on a single medicine. Until the court rules on the settlement, the Chinese green light speaks to additional therapeutic options in the pipeline, not to a secured contribution to the bottom line.
Ad
Bayer Stock: New Analysis - 4 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
